Breaking News Instant updates and real-time market news.

CMRX

Chimerix

$3.06 /

+0.235 (+8.33%)

07:13
11/05/20
11/05
07:13
11/05/20
07:13

Chimerix reports Q3 EPS (18c), consensus (17c)

Reports Q3 revenue $1.6M, consensus $960,000 "Throughout the third quarter we continued to make significant progress across a number of key initiatives," said Mike Sherman, CEO of Chimerix. "Of particular note was the completion of our rolling submissions to the U.S. Food and Drug Administration for the approval of brincidofovir as a medical countermeasure for smallpox. This milestone brings us one step closer to the company's first regulatory approval and to securing a potential procurement contract with BARDA to supply the U.S. Strategic National Stockpile, which we expect to take place around the time of a potential FDA approval. In addition, we expect to be notified of our Prescription Drug User Fee Act date relating to these submissions before the end of the year. In addition, we expect to initiate our Phase 3 study of DSTAT for the treatment of acute myeloid leukemia in early 2021. We were particularly encouraged by a recent meta-analysis of 11,151 patients covering 81 separate studies published in the Journal of the American Medical Association Oncology in which a link was suggested between minimal residual disease status and outcomes in patients with AML. Specifically, this large cohort meta-analysis showed that MRD-negative AML patients experience superior disease-free survival and overall survival rates when compared to patients that are MRD-positive. The study suggests that evaluation of MRD status in AML patients may allow for an earlier assessment of therapeutic effects and could lead to acceleration in the development of novel AML therapeutics. This meta-analysis underscores the importance of the MRD assessment that we will undertake following the first 80 evaluable patients in our Phase 3 study in order to better interpret the relapse-free survival and overall survival advantages observed with DSTAT in our smaller Phase 2 study. Due to the complex and rapidly changing landscape of the current pandemic, we cannot predict when we will complete enrollment in our Phase 2 trial of DSTAT in acute lung injury in COVID-19 but do anticipate sharing initial topline data in the first quarter of 2021."

  • 05

    Nov

CMRX Chimerix
$3.06 /

+0.235 (+8.33%)

05/21/20 JonesTrading
Chimerix initiated with a Buy at JonesTrading

TODAY'S FREE FLY STORIES

Conference/Events
Lowe's to host virtual analyst day » 21:00
12/04/20
12/04
21:00
12/04/20
21:00
LOW

Lowe's

$150.00 /

-1.845 (-1.22%)

Virtual Analyst Day to be…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
LOW Lowe's
$150.00 /

-1.845 (-1.22%)

LOW Lowe's
$150.00 /

-1.845 (-1.22%)

09:14 Today Morgan Stanley
Lowe's, Home Depot price targets raised at Morgan Stanley
11/18/20 Baird
Lowe's Q3 comps 'robust', Q4 EBIT margin guidance 'flattish', says Baird
11/18/20 Wells Fargo
Lowe's long-term transformation making progress, says Wells Fargo
11/18/20 Baird
Lowe's pullback likely a buying opportunity, says Baird
LOW Lowe's
$150.00 /

-1.845 (-1.22%)

LOW Lowe's
$150.00 /

-1.845 (-1.22%)

LOW Lowe's
$150.00 /

-1.845 (-1.22%)

LOW Lowe's
$150.00 /

-1.845 (-1.22%)

Hot Stocks
Crowdstrike CEO: Target is a great partner for us » 18:35
12/04/20
12/04
18:35
12/04/20
18:35
CRWD

Crowdstrike

$167.35 /

+6.15 (+3.82%)

In an interview on…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
CRWD Crowdstrike
$167.35 /

+6.15 (+3.82%)

CRWD Crowdstrike
$167.35 /

+6.15 (+3.82%)

06:46 Today Credit Suisse
Crowdstrike price target raised to $150 from $125 at Credit Suisse
06:27 Today BTIG
Crowdstrike price target raised to $190 from $164 at BTIG
12/03/20 FBN Securities
Crowdstrike price target raised to $200 from $150 at FBN Securities
12/03/20 DA Davidson
Crowdstrike price target raised to $185 from $160 at DA Davidson
CRWD Crowdstrike
$167.35 /

+6.15 (+3.82%)

  • 26
    Jun
  • 07
    Jan
  • 09
    Dec
CRWD Crowdstrike
$167.35 /

+6.15 (+3.82%)

CRWD Crowdstrike
$167.35 /

+6.15 (+3.82%)

CRWD Crowdstrike
$167.35 /

+6.15 (+3.82%)

Conference/Events
Mirum Pharmaceuticals to host virtual investor day » 18:13
12/04/20
12/04
18:13
12/04/20
18:13
MIRM

Mirum Pharmaceuticals

$23.90 /

+0.04 (+0.17%)

Virtual Investor Day to…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
MIRM Mirum Pharmaceuticals
$23.90 /

+0.04 (+0.17%)

MIRM Mirum Pharmaceuticals
$23.90 /

+0.04 (+0.17%)

11/30/20 Piper Sandler
Mirum continues to deliver on milestones, says Piper Sandler
11/13/20 Raymond James
Mirum Pharmaceuticals price target raised to $52 from $48 at Raymond James
10/15/20 Piper Sandler
Mirum putting cards in place for maralixibat rollout, says Piper Sandler
09/28/20 Piper Sandler
Mirum opportunity in Alagille syndrome higher than expected, says Piper Sandler
MIRM Mirum Pharmaceuticals
$23.90 /

+0.04 (+0.17%)

  • 09
    Jan
MIRM Mirum Pharmaceuticals
$23.90 /

+0.04 (+0.17%)

Conference/Events
Arcutis Biotherapeutics to host virtual investor day » 18:11
12/04/20
12/04
18:11
12/04/20
18:11
ARQT

Arcutis Biotherapeutics

$26.00 /

-0.57 (-2.15%)

Virtual Investor Day to…

Virtual Investor Day to be held on December 9 at 11 am. Webcast Link

ShowHide Related Items >><<
ARQT Arcutis Biotherapeutics
$26.00 /

-0.57 (-2.15%)

ARQT Arcutis Biotherapeutics
$26.00 /

-0.57 (-2.15%)

11/09/20 Goldman Sachs
Arcutis Biotherapeutics upgraded to Buy from Neutral at Goldman Sachs
10/08/20 Truist
Arcutis Biotherapeutics initiated with a Buy at Truist
10/08/20 Truist
Arcutis Biotherapeutics initiated with a Buy at Truist
03/20/20 Cantor Fitzgerald
Arcutis dermatology potential remains underappreciated, says Cantor Fitzgerald
ARQT Arcutis Biotherapeutics
$26.00 /

-0.57 (-2.15%)

  • 02
    Oct
  • 31
    Jan
ARQT Arcutis Biotherapeutics
$26.00 /

-0.57 (-2.15%)

Conference/Events
Lydall to host virtual investor day » 18:10
12/04/20
12/04
18:10
12/04/20
18:10
LDL

Lydall

$29.86 /

+1.23 (+4.30%)

Virtual Investor Day to…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
LDL Lydall
$29.86 /

+1.23 (+4.30%)

LDL Lydall
$29.86 /

+1.23 (+4.30%)

10/20/20 Sidoti
Lydall re-initiated with a Buy at Sidoti
03/10/20 Sidoti
Lydall upgraded to Buy from Neutral at Sidoti
Conference/Events
Agilent to hold a meeting » 18:07
12/04/20
12/04
18:07
12/04/20
18:07
A

Agilent

$115.18 /

+1.72 (+1.52%)

Virtual Analyst and…

Virtual Analyst and Investor Meeting to be held on December 9 at 10 am. Webcast Link

ShowHide Related Items >><<
A Agilent
$115.18 /

+1.72 (+1.52%)

A Agilent
$115.18 /

+1.72 (+1.52%)

12/02/20 Goldman Sachs
Agilent initiated with a Buy at Goldman Sachs
11/25/20
Fly Intel: Top five analyst upgrades
11/25/20 UBS
Agilent upgraded to Buy from Neutral at UBS
11/24/20 SVB Leerink
Agilent price target raised to $120 from $100 at SVB Leerink
A Agilent
$115.18 /

+1.72 (+1.52%)

A Agilent
$115.18 /

+1.72 (+1.52%)

A Agilent
$115.18 /

+1.72 (+1.52%)

Conference/Events
Nielsen to host virtual meeting » 18:04
12/04/20
12/04
18:04
12/04/20
18:04
NLSN

Nielsen

$17.97 /

+0.725 (+4.21%)

Virtual Investor Day to…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
NLSN Nielsen
$17.97 /

+0.725 (+4.21%)

NLSN Nielsen
$17.97 /

+0.725 (+4.21%)

11/03/20 Deutsche Bank
Nielsen price target lowered to $18 from $22 at Deutsche Bank
08/25/20 Truist
Nielsen price target lowered to $20 from $23 at Truist
05/28/20 Spin-Off Research
Nielsen upgraded to Hold from Sell at Spin-Off Research
05/21/20 Citi
Nielsen price target lowered to $18 from $28 at Citi
NLSN Nielsen
$17.97 /

+0.725 (+4.21%)

NLSN Nielsen
$17.97 /

+0.725 (+4.21%)

NLSN Nielsen
$17.97 /

+0.725 (+4.21%)

NLSN Nielsen
$17.97 /

+0.725 (+4.21%)

Conference/Events
Salesforce to host virtual investor day » 18:01
12/04/20
12/04
18:01
12/04/20
18:01
CRM

Salesforce

$225.50 /

+4.54 (+2.05%)

Virtual Investor Day to…

Virtual Investor Day to be held on December 8 at 1:30 pm.

ShowHide Related Items >><<
CRM Salesforce
$225.50 /

+4.54 (+2.05%)

CRM Salesforce
$225.50 /

+4.54 (+2.05%)

12/03/20 Wedbush
Slack Technologies upgraded to Neutral from Underperform at Wedbush
12/02/20 Needham
Salesforce Q3 results were 'mildly disappointing', says Needham
12/02/20 Citi
Citi not a fan of Slack acquisition, downgrades Salesforce to Neutral
12/02/20 Raymond James
Salesforce price target raised to $280 from $255 at Raymond James
CRM Salesforce
$225.50 /

+4.54 (+2.05%)

CRM Salesforce
$225.50 /

+4.54 (+2.05%)

CRM Salesforce
$225.50 /

+4.54 (+2.05%)

CRM Salesforce
$225.50 /

+4.54 (+2.05%)

Hot Stocks
Perma-Pipe International announces $6M in contract awards in Egypt » 17:58
12/04/20
12/04
17:58
12/04/20
17:58
PPIH

Perma-Pipe International

$5.67 /

+0.07 (+1.25%)

Perma-Pipe International…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

Conference/Events
H&R Block to host virtual investor day » 17:56
12/04/20
12/04
17:56
12/04/20
17:56
HRB

H&R Block

$18.19 /

+0.58 (+3.29%)

Virtual Investor Day to…

Virtual Investor Day to be held on December 8 at 10 am. Webcast Link

ShowHide Related Items >><<
HRB H&R Block
$18.19 /

+0.58 (+3.29%)

HRB H&R Block
$18.19 /

+0.58 (+3.29%)

10/30/20 BTIG
BTIG thinks those looking to potentially short Square, H&R Block should wait
09/03/20 BMO Capital
H&R Block price target lowered to $17 from $19 at BMO Capital
09/01/20 BTIG
H&R Block's tax season distorted by pandemic, say BTIG
07/15/20 Northcoast
H&R Block upgraded to Buy from Neutral at Northcoast
HRB H&R Block
$18.19 /

+0.58 (+3.29%)

HRB H&R Block
$18.19 /

+0.58 (+3.29%)

HRB H&R Block
$18.19 /

+0.58 (+3.29%)

Conference/Events
Syneos Health to hold virtual analyst and investor meeting » 17:52
12/04/20
12/04
17:52
12/04/20
17:52
SYNH

Syneos Health

$38.00 /

+17 (+9.00%)

Virtual Analyst and…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SYNH Syneos Health
$38.00 /

+17 (+9.00%)

SYNH Syneos Health
$38.00 /

+17 (+9.00%)

10/06/20 Mizuho
Syneos Health upgraded to Buy on attractive entry point at Mizuho
10/06/20 Mizuho
Syneos Health upgraded to Buy on attractive entry point at Mizuho
10/06/20 Mizuho
Syneos Health upgraded to Buy from Neutral at Mizuho
10/06/20 Mizuho
Syneos Health upgraded to Buy from Neutral at Mizuho
10/01/20 Goldman Sachs
Syneos Health upgraded to Buy from Neutral at Goldman Sachs
10/01/20 Goldman Sachs
Syneos Health upgraded to Buy from Neutral at Goldman Sachs
08/12/20 Truist
Syneos Health price target raised to $80 from $74 at Truist
08/12/20 Truist
Syneos Health price target raised to $80 from $74 at Truist
SYNH Syneos Health
$38.00 /

+17 (+9.00%)

  • 02
    Dec
  • 02
    Dec
  • 16
    Sep
  • 16
    Sep
SYNH Syneos Health
$38.00 /

+17 (+9.00%)

Conference/Events
Secureworks to host virtual investor day » 17:50
12/04/20
12/04
17:50
12/04/20
17:50
SCWX

Secureworks

$12.31 /

-0.03 (-0.24%)

Virtual Investor Day to…

Virtual Investor Day to be held on December 8 at 9 am. Webcast Link

ShowHide Related Items >><<
SCWX Secureworks
$12.31 /

-0.03 (-0.24%)

SCWX Secureworks
$12.31 /

-0.03 (-0.24%)

03/20/20 Goldman Sachs
Secureworks upgraded to Neutral from Sell at Goldman Sachs
SCWX Secureworks
$12.31 /

-0.03 (-0.24%)

Conference/Events
Enbridge to host virtual investor meeting » 17:48
12/04/20
12/04
17:48
12/04/20
17:48
ENB

Enbridge

$33.37 /

+0.64 (+1.96%)

Virtual Investor meeting…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ENB Enbridge
$33.37 /

+0.64 (+1.96%)

ENB Enbridge
$33.37 /

+0.64 (+1.96%)

11/30/20 Wells Fargo
Enbridge upgraded to Overweight from Equal Weight at Wells Fargo
11/09/20 RBC Capital
Enbridge price target lowered to C$52 from C$58 at RBC Capital
11/09/20 National Bank
Enbridge price target lowered to C$55 from C$56 at National Bank
11/09/20 Stifel
Enbridge price target lowered to C$59 from C$61 at Stifel
ENB Enbridge
$33.37 /

+0.64 (+1.96%)

ENB Enbridge
$33.37 /

+0.64 (+1.96%)

ENB Enbridge
$33.37 /

+0.64 (+1.96%)

Hot Stocks
MGM Resorts CFO Corey Sanders appointed as COO » 17:46
12/04/20
12/04
17:46
12/04/20
17:46
MGM

MGM Resorts

$30.73 /

+0.81 (+2.71%)

On December 4, 2020, MGM…

On December 4, 2020, MGM Resorts announced that Corey Sanders has been appointed Chief Operating Officer, effective December 4, 2020. Mr. Sanders will continue to serve as CFO and Treasurer until a replacement is hired and is in place. Mr. Sanders has served as CFO and Treasurer of the Company since March 2019 and previously as Chief Operating Officer of the company from 2010 to March 2019.

ShowHide Related Items >><<
MGM MGM Resorts
$30.73 /

+0.81 (+2.71%)

MGM MGM Resorts
$30.73 /

+0.81 (+2.71%)

12/03/20 Deutsche Bank
MGM Resorts price target raised to $24 from $18 at Deutsche Bank
12/02/20 Macquarie
MGM Resorts price target raised to $32 from $29 at Macquarie
11/30/20 Truist
MGM Resorts price target raised to $32 from $22 at Truist
11/10/20 Wells Fargo
IAC price target raised to $165 from $155 at Wells Fargo
MGM MGM Resorts
$30.73 /

+0.81 (+2.71%)

MGM MGM Resorts
$30.73 /

+0.81 (+2.71%)

MGM MGM Resorts
$30.73 /

+0.81 (+2.71%)

MGM MGM Resorts
$30.73 /

+0.81 (+2.71%)

Hot Stocks
Lipocine says FDA continuing to work towards action on TLANDO NDA » 17:46
12/04/20
12/04
17:46
12/04/20
17:46
LPCN

Lipocine

$1.55 /

-0.025 (-1.59%)

Lipocine announced that…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
LPCN Lipocine
$1.55 /

-0.025 (-1.59%)

LPCN Lipocine
$1.55 /

-0.025 (-1.59%)

05/27/20 H.C. Wainwright
Lipocine price target raised to $3 from $2 at H.C. Wainwright
LPCN Lipocine
$1.55 /

-0.025 (-1.59%)

LPCN Lipocine
$1.55 /

-0.025 (-1.59%)

LPCN Lipocine
$1.55 /

-0.025 (-1.59%)

Conference/Events
Incyte to hold a conference call » 17:46
12/04/20
12/04
17:46
12/04/20
17:46
INCY

Incyte

$83.14 /

+0.47 (+0.57%)

Management discusses…

Management discusses detailed results from the pivotal Phase 3 REACH3 study as presented at the ASH 62nd Annual Meeting on a conference call to be held on December 7 at 10 am. Webcast Link

ShowHide Related Items >><<
INCY Incyte
$83.14 /

+0.47 (+0.57%)

INCY Incyte
$83.14 /

+0.47 (+0.57%)

11/06/20 RBC Capital
Incyte price target lowered to $86 from $96 at RBC Capital
09/18/20 Piper Sandler
Piper Sandler lays out next potential takeover targets in oncology
09/14/20 Mizuho
Oncology 'fertile ground for M&A activity,' says Mizuho
08/05/20 Mizuho
Incyte price target raised to $95 from $79 at Mizuho
INCY Incyte
$83.14 /

+0.47 (+0.57%)

INCY Incyte
$83.14 /

+0.47 (+0.57%)

Conference/Events
Equifax to host conference call » 17:41
12/04/20
12/04
17:41
12/04/20
17:41
EFX

Equifax

$166.57 /

+1.485 (+0.90%)

CEO Begor and CFO Gamble…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
EFX Equifax
$166.57 /

+1.485 (+0.90%)

EFX Equifax
$166.57 /

+1.485 (+0.90%)

10/28/20 Truist
TransUnion price target lowered to $100 from $110 at Truist
10/26/20 Argus
Equifax's 'relatively high leverage' may prove 'troublesome', says Argus
10/07/20 Exane BNP Paribas
Equifax upgraded to Outperform from Neutral at Exane BNP Paribas
10/06/20
Fly Intel: Top five analyst initiations
EFX Equifax
$166.57 /

+1.485 (+0.90%)

EFX Equifax
$166.57 /

+1.485 (+0.90%)

EFX Equifax
$166.57 /

+1.485 (+0.90%)

EFX Equifax
$166.57 /

+1.485 (+0.90%)

Conference/Events
Cantor Fitzgerald healthcare analysts hold analyst/industry conference call » 17:37
12/04/20
12/04
17:37
12/04/20
17:37
CLDX

Celldex

$19.59 /

-0.205 (-1.04%)

Healthcare &…

Healthcare & Pharmaceuticals Analysts discuss Celldex Therapeutics' CDX-0159 and the Chronic Urticaria Landscape on an Analyst/Industry conference call to be held on December 10 at 10 am.

ShowHide Related Items >><<
CLDX Celldex
$19.59 /

-0.205 (-1.04%)

CLDX Celldex
$19.59 /

-0.205 (-1.04%)

10/19/20 H.C. Wainwright
Celldex price target raised to $25 from $16 at H.C. Wainwright
07/01/20 Cantor Fitzgerald
Celldex price target raised to $18 from $12 at Cantor Fitzgerald
06/12/20 Cantor Fitzgerald
Celldex price target raised to $12 from $8 at Cantor Fitzgerald
02/21/20
Fly Intel: Top five analyst initiations
CLDX Celldex
$19.59 /

-0.205 (-1.04%)

  • 16
    Jun
CLDX Celldex
$19.59 /

-0.205 (-1.04%)

Periodicals
Citi scales back staff in New York-area offices, Bloomberg reports » 17:36
12/04/20
12/04
17:36
12/04/20
17:36
C

Citi

$58.62 /

+2.05 (+3.62%)

Citigroup is cutting…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
C Citi
$58.62 /

+2.05 (+3.62%)

C Citi
$58.62 /

+2.05 (+3.62%)

11/30/20 Morgan Stanley
Morgan Stanley upgrades Large Cap Banks & Consumer Finance to Attractive
11/18/20 Keefe Bruyette
Citi upgraded to Outperform from Market Perform at Keefe Bruyette
10/22/20
Fly Intel: Top five analyst downgrades
10/22/20 Goldman Sachs
Citi downgraded to Buy from Conviction Buy at Goldman Sachs
C Citi
$58.62 /

+2.05 (+3.62%)

C Citi
$58.62 /

+2.05 (+3.62%)

C Citi
$58.62 /

+2.05 (+3.62%)

C Citi
$58.62 /

+2.05 (+3.62%)

Conference/Events
MKM Partners retail/softlines analyst to hold analyst/industry conference call » 17:35
12/04/20
12/04
17:35
12/04/20
17:35

Analyst Meyer will…

Analyst Meyer will discuss the Softlines Retail Industry on an Analyst/Industry conference call to be held on December 9.

Conference/Events
Cantor Fitzgerald consumer goods analyst holds analyst/industry conference call » 17:34
12/04/20
12/04
17:34
12/04/20
17:34

Consumer Goods Analysts,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

Conference/Events
BTIG medical technology analyst to hold analyst/industry conference call » 17:32
12/04/20
12/04
17:32
12/04/20
17:32

Medical Technology and…

Medical Technology and Digital Health Analyst Thibault discusses the latest devices and treatment approaches for venous thrombo embolism on an Analyst/Industry conference call to be held on December 7 at 10 am.

Conference/Events
Stephens healthcare services analyst holds analyst/industry conference call » 17:30
12/04/20
12/04
17:30
12/04/20
17:30

Healthcare Services…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

Conference/Events
Morgan Stanley ESG analysts to hold an analyst/industry conference call » 17:29
12/04/20
12/04
17:29
12/04/20
17:29

Asia ESG Research Analyst…

Asia ESG Research Analyst Chan, China Autos and Shared Mobility Analyst Hsiao, Asia Utilities Analyst Lee, Asia Specialist Sales Analyst Dean discuss the coming of Environmental, Social and Corporate Governance in Asia and Morgan Stanley best ideas on an Analyst/Industry conference call to be held on December 8 at 8:30 am.

Conference/Events
Compass Point financial analyst to hold analyst/industry conference call » 17:27
12/04/20
12/04
17:27
12/04/20
17:27
ARCC

Ares Capital

$17.28 /

+0.005 (+0.03%)

Financial Analysts, along…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ARCC Ares Capital
$17.28 /

+0.005 (+0.03%)

10/27/20 Janney Montgomery Scott
Ares Capital upgraded to Buy on NAV gains at Janney Montgomery Scott
10/27/20 Janney Montgomery Scott
Ares Capital upgraded to Buy from Neutral at Janney Montgomery Scott
08/05/20 Citi
Ares Capital price target raised to $17 from $15 at Citi
05/07/20 Citi
Ares Capital price target raised to $15 from $13 at Citi
ARCC Ares Capital
$17.28 /

+0.005 (+0.03%)

ARCC Ares Capital
$17.28 /

+0.005 (+0.03%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.